Evidence map›Paper›PMID 42353281›Full record

ArticleInternational journal of molecular sciences2026

CTLA-4 Blockade Combined with PD-1/PD-L1 Inhibition Enhances Cytokine Production and T-Cell Activation in Ex Vivo Ovarian Cancer Cultures.

Maitreyee Parulekar, Wook Ha Park, Miseon Kim, Kidong Kim, Jae Hong No, Yong Beom Kim, Dong Hoon Suh

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maitreyee ParulekarDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
Wook Ha ParkDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
Miseon KimDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
Kidong KimDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
Jae Hong NoDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.ORCID 0000-0002-2389-6757
Yong Beom KimDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.ORCID 0000-0003-1196-369X
Dong Hoon SuhDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.ORCID 0000-0002-4312-966X

Funding

Ministry of Science and ICT NRF-2017R1D1A1B03035014
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) show promise in cancer but have limited efficacy in ovarian cancer. This study compared combinations of the PD-1/PD-L1 inhibitor with anti-LAG-3, anti-TIM-3, or anti-CTLA-4 to identify the most effective regimen by assessing T-cell CD8/CD4 ratios and cytokine production. T cells isolated from ovarian cancer tissues (mean 3.8 × 10

Indexed as

B7-H1 AntigenCTLA-4 AntigenCytokinesImmune Checkpoint InhibitorsLymphocyte ActivationOvarian NeoplasmsProgrammed Cell Death 1 ReceptorT-LymphocytesCD8-Positive T-LymphocytesFemaleHumansLymphocyte Activation Gene 3 ProteinB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanCytokinesImmune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptorimmunotherapyovarian cancerprogrammed cell death 1 proteinT lymphocytes

Identifiers

PMID42353281
PMCPMC13300639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.